Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate-risk rhabdomyosarcoma: A report from Children's Oncology Group.
Sara J IsraelsAmria QumseyaWei XueDouglas J HarrisonErin R RudzinskiSuzanne L WoldenRoshni DasguptaRajkumar VenkatramaniAbha A GuptaPublished in: Pediatric blood & cancer (2023)
/dose during VAC/VI chemotherapy was feasible and well tolerated. The efficacy of this regimen is currently being tested in a phase III randomized trial against VAC/VI chemotherapy alone in the ARST1431 trial.